Syngene has to be looked at from multi-year perspective and not 2-3 years because even at this scale it is just at a nascent stage relative to its opportunity landscape…….financial parameters like eps, etc., could be variable depending on strategy it adopts but visibility of sustaining at least 20% pa top line growth with 30% + EBITDA margins along with maintaining historical EBITDA to ocf conversion rate is quite high…..
Rgds.
| Subscribe To Our Free Newsletter |
